Fontolizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fontolizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target interferon gamma
Clinical data
Legal status ?
Identifiers
CAS number 326859-36-3 N
ATC code None
UNII 6J92H2439Z YesY
KEGG D04242 YesY
Chemical data
Formula ?
Mol. mass ca. 150 kDa
 N (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  2. ^ Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. 
  3. ^ ClinicalTrials.gov NCT00281294 A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis